Related Experiment Video

Updated: Aug 14, 2026

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Phenobarbital in the acute management of febrile convulsions

J L Pearce, J R Sharman, R M Forster

    Pediatrics
    |October 1, 1977
    PubMed

    Insights

    Oral phenobarbital at 15 mg/kg provides therapeutic blood levels in children within 90 minutes for managing febrile convulsions. Intramuscular administration showed inconsistent absorption, making it less suitable for acute seizure control.

    Area of Science:

    • Pediatric Neurology
    • Clinical Pharmacology

    Background:

    • Febrile convulsions are common in children.
    • Phenobarbital is a widely used anticonvulsant medication.

    Purpose of the Study:

    • To compare the pharmacokinetics of oral versus intramuscular phenobarbital in children after febrile convulsions.
    • To determine the optimal route and timing for phenobarbital administration in pediatric seizure management.

    Main Methods:

    • Children hospitalized for febrile convulsions received a single oral or intramuscular dose of phenobarbital (15 mg/kg).
    • Blood phenobarbital levels were monitored over time to assess absorption and therapeutic efficacy.
    • Pharmacokinetic parameters were analyzed for both administration routes.

    Main Results:

    • Both oral and intramuscular routes achieved therapeutic phenobarbital blood levels within 90 minutes at a 15 mg/kg dose.
    • Intramuscular absorption was inconsistent before 90 minutes, potentially delaying seizure control.
    • Oral administration demonstrated more reliable and predictable absorption for acute management.

    Conclusions:

    • Oral phenobarbital at 15 mg/kg is a viable option for managing febrile convulsions in children.
    • Further research is warranted to confirm the efficacy of oral phenobarbital for seizure prevention.
    • Intramuscular phenobarbital may be less reliable for rapid seizure termination due to absorption variability.

    More Related Videos

    Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits10:25

    Multi-system Monitoring for Identification of Seizures, Arrhythmias and Apnea in Conscious Restrained Rabbits

    Published on: March 27, 2021

    Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits06:46

    Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits

    Published on: February 28, 2025

    Related Concept Videos

    CNS Depressants: Barbiturates and Benzodiazepines01:14

    CNS Depressants: Barbiturates and Benzodiazepines

    CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
    Sedatives and Hypnotics Drugs: Barbiturates01:20

    Sedatives and Hypnotics Drugs: Barbiturates

    Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
    Antiepileptic Drugs: Sodium Channel Blockers01:08

    Antiepileptic Drugs: Sodium Channel Blockers

    Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
    Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
    Among the most commonly prescribed antiepileptic drugs are...
    Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

    Antiepileptic Drugs: GABAergic Pathway Potentiators

    γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
    The key GABA pathway potentiators used in epilepsy management are as follows.
    Benzodiazepines are a well-known class of drugs used for their...
    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

    Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
    SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
    Antiepileptic Drugs: Potassium Channel Activators01:20

    Antiepileptic Drugs: Potassium Channel Activators

    Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
    Ezogabine has gained approval as an adjunctive treatment...